Dr. Robert Johnson -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Robert Johnson, a Infectious Disease physician based in Cleveland, OH. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Robert Johnson has received $20,761.24 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Robert Johnson
- Medical Specialty: Infectious Disease
- Practice Location: Cleveland, OH, Ohio
- NPI Number: 1130110694
- Transparency Score: 100/100
- Payment Records Span: 2026-03-29 to 2026-03-29
Payment Summary
Dr. Robert Johnson has received a total of $20,761.24 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $20,761.24 per transaction.
- Total Payments Received: $20,761.24
- Number of Transactions: 1
- Average Payment: $20,761.24
- Transparency Score: 100/100 -- This score reflects the overall payment profile relative to peers in Infectious Disease. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Robert Johnson's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Speaking & Education | $20,761.24 | Promotional speaking, CME events, and educational presentations |
The largest payment category for Dr. Robert Johnson is Speaking & Education, accounting for 100% ($20,761.24) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Robert Johnson. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Merck & Co | $20,761.24 | 1 |
Dr. Robert Johnson has a financial relationship with Merck & Co, receiving $20,761.24 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Robert Johnson. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Tagrisso -- Referenced in payment records from pharmaceutical companies to Dr. Robert Johnson
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Robert Johnson's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Robert Johnson has received $20.8K across 1 pharmaceutical payments as a Infectious Disease physician in Cleveland, OH. Top paying companies include Merck & Co ($20.8K). Dr. Johnson received a single payment of $20,761 in 2026, indicating a significant but isolated financial interaction. The entire payment was associated with speaking engagements, suggesting a focus on educational or promotional activities. Merck & Co. was the sole payer, and the payment was linked to the drug Tagrisso, highlighting a specific relationship with this company and product.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Robert Johnson is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When consulting with Dr. Johnson, consider asking about their relationships with pharmaceutical companies and how these relationships might influence treatment recommendations, especially concerning specific drugs like Tagrisso. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. Robert Johnson Compares to Other Infectious Disease Physicians
For an Infectious Disease specialist, Dr. Johnson's payment profile is highly concentrated with one company and one drug, which is less common than more diversified payment structures seen in the specialty.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Robert Johnson in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Merck & Co | $20,761.24 | speaking | Tagrisso | 2026-03-29 | Not Assessed |
Frequently Asked Questions About Dr. Robert Johnson's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has Robert Johnson received?
Robert Johnson has received a total of $20.8K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is Robert Johnson taking too much pharma money?
Robert Johnson has received $20.8K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Infectious Disease), the types of payments, and how they compare to peers. The largest payment category is speaking ($20.8K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay Robert Johnson?
The top pharmaceutical companies paying Robert Johnson are: Merck & Co ($20.8K). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does Robert Johnson receive?
Robert Johnson's payments by type: speaking: $20.8K.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do Robert Johnson's payments compare to other Infectious Disease doctors?
To compare, look at the total amount ($20.8K), number of payments (1), and the types of payments received. Infectious Disease physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify Robert Johnson's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1130110694). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about Robert Johnson's pharma payment profile?
The doctor's payment profile is highly concentrated, with 100% of the total amount coming from a single company (Merck & Co.). Robert Johnson has received $20.8K in total pharma payments.
How does Robert Johnson compare to peers in Infectious Disease?
For an Infectious Disease specialist, Dr. Johnson's payment profile is highly concentrated with one company and one drug, which is less common than more diversified payment structures seen in the specialty.
Are Robert Johnson's pharma relationships typical for Infectious Disease?
The payment is exclusively categorized under 'speaking' fees, with no other payment types listed.
What should patients of Robert Johnson know about these payments?
When consulting with Dr. Johnson, consider asking about their relationships with pharmaceutical companies and how these relationships might influence treatment recommendations, especially concerning specific drugs like Tagrisso.
What patterns are visible in Robert Johnson's payment history?
A single drug, Tagrisso, accounts for the entire reported payment amount.
Understanding This Doctor Payment Report
This transparency report for Dr. Robert Johnson is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Infectious Disease physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Robert Johnson's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Robert Johnson and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Infectious Disease Specialty Payment Data -- See payment patterns for all infectious disease physicians
- Ohio Physician Payments -- Browse pharmaceutical payments to physicians in Ohio
- Infectious Disease Physicians in Ohio -- Compare Dr. Robert Johnson to peers in the same state and specialty
- Merck & Co Payment Profile -- View all payments made by Dr. Robert Johnson's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Robert Johnson's NPI (1130110694) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.